Skip to main content
. 2004 Jan 15;10(2):273–278. doi: 10.3748/wjg.v10.i2.273

Table 5.

Utilization and costs of drugs related to gastroenterological diseases among cohorts (n = 183 976) in 2001, by the fourth level of ATC classification system

ATC code Drug group name No. of patients No. of orders Total cost
US $ % Cum. %
A02BA H2-receptor antagonists 26 690 85 228 269 851 17.4% 17.4%
A02BC Proton pump inhibitors 2 223 7 100 219 823 14.2% 31.6%
A02AF Antacids with antiflatulents 98 197 385 623 156 244 10.1% 41.6%
A05BA Liver therapy 3 234 12 990 113 482 7.3% 49.0%
A02AD Combinations and complexes of aluminium, 83 569 305 357 108 399 7.0% 55.9%
calcium and magnesium compounds
A03FA Propulsives 46 418 140 278 108 006 7.0% 62.9%
A02AB Aluminium compounds 20 845 50 850 71 820 4.6% 67.5%
A06AB Contact laxatives 8 775 37 266 59 022 3.8% 71.3%
A02AG Antacids with antispasmodics 53 966 160 086 52 394 3.4% 74.7%
A06AC Bulk producers 2 327 5 851 47 848 3.1% 77.8%
A09AA Enzyme preparations 15 041 37 149 35 754 2.3% 80.1%
A03AA Synthetic anticholinergics, esters with 19 071 43 779 28 953 1.9% 82.0%
tertiary amino group
A07EC Aminosalicylic acid and similar agents 248 1 504 24 494 1.6% 83.6%
A03AX Other synthetic anticholinergic agents 2 264 4 110 22 682 1.5% 85.0%
A04AA Serotonin (5HT3) antagonists 108 375 22 612 1.5% 86.5%
A02DA Antiflatulents 38 126 97 683 16 448 1.1% 87.5%
A03AB Synthetic anticholinergics, quaternary 8 413 15 312 16 205 1.0% 88.6%
ammonium compounds
A03BB Belladonna alkaloids, semisynthetic, 20 940 39 494 15 415 1.0% 89.6%
quaternary ammonium compounds
A06AD Osmotically acting laxatives 513 1 485 15 401 1.0% 90.6%
A05AA Bile acid preparations 409 1 580 15 064 1.0% 91.5%
Others 131 330 8.5% 100.0%
Totala 149 062 1719 500 1 551 250 100.0%
a

Numbers might not add to totals because of rounding.

HHS Vulnerability Disclosure